Real-life practice: rapid improvement in itch symptomatology in patients with atopic dermatitis treated with dupilumab

Clinical Response and Quality of Life in Patients with Severe Atopic Dermatitis Treated with Dupilumab: A Single-Center Real-Life Experience

“…In this regard, dupilumab (Dupixent ® ), a fully human monoclonal antibody inhibiting the interleukin (IL)-4/IL-13 signaling through the blockade of the IL-4 receptor α subunit, has been recently approved by both the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for the treatment of patients with moderate-to-severe inadequately controlled AD [6]. However, although dupilumab has been demonstrated to be an effective and safe therapeutic option by the two identical phase-3 SOLO1 and SOLO2 trials [7] and the LIBERTY AD CHRONOS [8] and LIBERTY AD CAFÉ [9] phase-3 trials, literature data resulting from a real-life daily practice setting are limited [10][11][12][13][14][15][16][17][18]. Therefore, with the aim of identifying possible predictors of response to dupilumab and assessing the clinical response to this drug in terms of quality of life and disease severity improvement, we retrospectively assessed cases of severe AD treated with dupilumab for a period of at least 16 weeks at our Department.…”

Mesenchymal Stem Cells and Atopic Dermatitis: A Review

“…Systemic therapy may be offered to those with severe disease or treatment-resistant eczema, however, invariably, in the long term, comes along with side effects (Apfelbacher et al, 2013;Wong et al, 2017;Aoki et al, 2019). New therapeutic approaches, such as monoclonal antibodies, are passing through the drug discovery pipeline and may reinforce the therapeutic arsenal against AD in a near future (Weidinger and Novak, 2016;Snast et al, 2018;Pistone et al, 2019).…”

Ocular surface disease during dupilumab treatment in patients with atopic dermatitis, is it possible to prevent it?

“…This drug is a human monoclonal antibody directed against the shared a subunit of the interleukin (IL)-4 and IL-13 receptor approved for adult patients affected by moderate-to-severe AD. 1,2 Clinical trials and real-life data have demonstrated efficacy and safety of this treatment; however, trials have also shown an increased incidence of conjunctivitis. 3 Indeed, it would be more correct to use the term of ocular surface disease (OSD), an umbrella term that includes all types of dupilumab-induced ocular inflammation including dry eye, conjunctivitis and keratitis.…”

“…The drug is the first biological being licensed for atopic eczema (AE). 1,2 In pregnancy, AE frequently shows a deleterious course and may relevantly impact on quality of life. [3][4][5] According to the European Task force on Atopic Dermatitis (ETFAD), when treating pregnant and lactating women with AE, systemic treatment should be restricted to glucocorticosteroids, cyclosporine and azathioprine.…”

“…There have been only few data about dupilumab in pregnancy and lactation. 1,2 A possible passage and even active transport and up-concentration across the placentas should be considered. 6 However, animal studies did not show any direct or indirect harmful influence of dupilumab on reproduction.…”